初代細胞培養の世界市場規模：製品別、用途別、細胞タイプ別、地域範囲別、予測

初代細胞培養の市場規模と予測

初代細胞培養市場規模は、2024年に45億3,000万米ドルと評価され、2026年から2032年にかけて11.37%のCAGRで成長し、2032年には107億1,000万米ドルに達すると予測されています。

• 初代細胞培養は、細胞を組織から直接分離し、管理された実験室条件下で増殖させるプロセスです。
• 研究開発における初代細胞培養の重要性が高まっているのは、生物内の細胞の生理的挙動を忠実に模倣し、より正確な研究モデルを提供できるからです。
• この方法では、細胞は通常、生きている生物から採取され、自然の状態に大きな変化を与えることなく培養されるため、重要な生物学的特性が確実に保持されます。
• 1次細胞培養の開発は、創薬、毒物学、がん研究、再生医療などの分野で増加しており、細胞の挙動を研究し、治療薬を試験し、個別化治療を開発するために使用されています。
• より正確で信頼性の高いin vitroモデルに対する要求の高まりは、連続的な細胞株と比較してin vivoの条件に近いことから、初代細胞の使用をさらに後押ししています。
• 培養中の初代細胞の増殖には、細胞の生存能と機能を維持するために注意深く調節された、特定の増殖因子と栄養素の存在が必要です。
• サイトカインやホルモンなどの成長因子は、これらの培養において細胞の増殖、分化、生存を促進するために不可欠です。

初代細胞培養の世界市場力学

世界の初代細胞培養市場を形成している主な市場力学は以下の通り：

主な促進要因

• 個別化医療に対する需要の高まり：個別化医療と精密医療への関心の高まりは、これらの細胞が患者に特化した治療法の開発に不可欠であることから、初代細胞培養市場を牽引すると予想されます。この市場は、正確な試験管内モデルを必要とする先端医療への投資の増加から恩恵を受けると予想されます。個別化医療連合（Personalized Medicine Coalition）によると、開発中の個別化医薬品の数は2017年から2022年の間に34%増加し、286以上の治療法に達しました。
• 創薬と開発への注力：創薬への注目が高まるにつれ、特に有効性と毒性を試験するための初代細胞培養の採用が加速すると予測されます。これらの細胞は、より信頼性の高いヒトベースの細胞モデルを提供することで、動物実験への依存を減らす上で重要な役割を果たすと思われます。
• がん研究への投資：がん研究への投資は高く、これらの培養細胞はがん細胞の挙動研究に広く使用されており、1次細胞培養市場の活性化につながると予想されます。世界のがん罹患率の上昇は、高度な細胞モデルに対する需要を押し上げ、市場成長を増大させると予想されます。
• 3D細胞培養の利用拡大：3D細胞培養は、従来の2D培養よりも生体内環境をより効果的に再現できることから、研究への採用は初代細胞の関連性を高めると推定されます。この動向は、様々な研究領域における初代細胞培養の応用範囲を拡大すると予想されます。VMRによると、3D細胞培養市場規模は2022年に18億8,000万米ドルとなり、2023年から2030年までのCAGRは10.87%で、2030年には43億米ドルに達すると予測されています。

主な課題

• 初代細胞培養の高コスト：初代細胞培養プロセスに関連する高コストは、特に研究資金が限られている地域では、市場の成長を抑制すると予想されます。初代細胞の調達と特定の増殖条件の維持にかかる費用は、市場拡大にとって重要な課題になると予想されます。
• 技術的複雑性と変動性：初代細胞培養の技術的複雑さと固有のばらつきは、普及の妨げになる可能性が高いです。この課題は、大規模研究および産業応用におけるスケーラビリティと再現性を制限すると予測されます。
• プライマリー細胞の限られた入手可能性：培養用のヒト組織や動物組織の調達が依然として困難であるため、高品質な初代細胞の入手可能性が限られていることが、市場の成長を妨げると予想されます。組織の調達にまつわる倫理的な懸念や規制上の制限が、サプライチェーンをさらに制約すると予想されます。
• 汚染リスクと寿命の短さ：不死化細胞株と比較して、プライマリー細胞は汚染リスクが高く、寿命が短いことが市場を抑制する可能性が高いです。これらの制限により、研究室の運営上の課題が増加し、長期研究の効率が低下することが予想されます。

主要動向

• 幹細胞研究への注目：再生医療において高品質の初代細胞が必要とされることから、幹細胞研究が重視されるようになり、1次細胞培養市場に大きな影響を与えることが予想されます。この動向は、バイオテクノロジーや製薬セクター全体の研究開発への投資を強化する可能性が高いです。
• 学術機関と産業界の連携：学術機関とバイオ医薬品企業とのパートナーシップの拡大は、初代細胞培養市場を後押しすると予測されます。このような共同研究は、技術革新を促進し、新しい細胞ベースの治療法や研究ツールの商業化を促進すると予測されます。
• 高度組織工学への需要：高度な組織工学ソリューションに対する高い需要が、研究や臨床応用における初代細胞培養の採用を促進すると予想されます。この動向は、オルガノイドやバイオエンジニアリング組織の開発に新たな道を開き、市場の可能性をさらに拡大すると思われます。

目次

第1章 世界の初代細胞培養市場の導入

• 市場の導入
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の初代細胞培養市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 初代細胞培養の世界市場、製品別

• 概要
• 初代細胞
• 試薬とサプリメント
• 細胞培養用培地

第6章 初代細胞培養の世界市場：用途別

• 概要
• ワクチン製造
• 幹細胞治療
• がん研究
• その他

第7章 初代細胞培養の世界市場、細胞タイプ別

• 概要
• 動物細胞
• ヒト細胞

第8章 初代細胞培養の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の初代細胞培養市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Lonza
• Merck KGaA
• Axol Bioscience Ltd
• GE Healthcare
• STEMCELL Technologies Inc
• Cell Biologics
• ZenBio
• ScienCell Research Laboratories
• PPA Research Group

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Primary Cell Culture Market Size And Forecast

Primary Cell Culture Market size was valued at USD 4.53 Billion in 2024 and is projected to reach USD 10.71 Billion by 2032, growing at a CAGR of 11.37% from 2026 to 2032.

• Primary cell culture is the process by which cells are isolated directly from tissues and grown under controlled laboratory conditions.
• The growing importance of primary cell culture in research and development is attributed to its ability to closely mimic the physiological behavior of cells within an organism, providing more accurate study models.
• In this method, cells are typically harvested from a living organism and cultured without significant alterations to their natural state, ensuring the retention of critical biological characteristics.
• Applications of primary cell cultures are rising in fields such as drug discovery, toxicology, cancer research, and regenerative medicine, where they are used to study cell behavior, test therapeutic agents, and develop personalized treatments.
• The increasing demand for more precise and reliable in vitro models has further driven the use of primary cells, given their closer resemblance to in vivo conditions compared to continuous cell lines.
• The growth of primary cells in culture requires the presence of specific growth factors and nutrients, which are carefully regulated to maintain cellular viability and function.
• Growth factors, such as cytokines and hormones, are essential for promoting cell proliferation, differentiation, and survival in these cultures.

Global Primary Cell Culture Market Dynamics

The key market dynamics that are shaping the global primary cell culture market include:

Key Drivers:

• Growing Demand for Personalized Medicine: The rising interest in personalized and precision medicine is anticipated to drive the primary cell culture market, as these cells are integral to developing patient-specific therapies. The market is expected to benefit from increasing investments in advanced medical treatments that require accurate in vitro models. According to the Personalized Medicine Coalition, the number of personalized medicines in development increased by 34% between 2017 and 2022, reaching over 286 therapies.
• Focus on Drug Discovery and Development: The increasing focus on drug discovery is projected to accelerate the adoption of primary cell cultures, especially for testing efficacy and toxicity. These cells are likely to play a critical role in reducing reliance on animal testing by offering more reliable human-based cell models.
• Investments in Cancer Research: High investments in oncology research are expected to fuel the primary cell culture market, with these cultures being widely used in studying cancer cell behavior. Rising cancer incidence globally is anticipated to boost demand for advanced cellular models, increasing market growth.
• Growing Use of 3D Cell Cultures: The adoption of 3D cell cultures in research is estimated to enhance the relevance of primary cells, given their ability to replicate in vivo environments more effectively than traditional 2D cultures. This trend is expected to expand the application range of primary cell cultures in various research domains. According to VMR, 3D Cell Culture Market size was valued at USD 1.88 Billion in 2022 and is projected to reach USD 4.30 Billion in 2030, at a CAGR of 10.87% from 2023 to 2030.

Key Challenges:

• High Costs of Primary Cell Cultures: The high costs associated with primary cell culture processes are anticipated to restrain market growth, particularly in regions with limited research funding. The expense of procuring primary cells and maintaining specific growth conditions is expected to be a key challenge for market expansion.
• Technical Complexity and Variability: The technical complexity and inherent variability of primary cell cultures are likely to impede widespread adoption. This challenge is projected to limit scalability and reproducibility in large-scale research and industrial applications.
• Limited Availability of Primary Cells: The limited availability of high-quality primary cells is expected to hamper market growth, as sourcing human or animal tissues for these cultures remains difficult. Ethical concerns and regulatory restrictions around tissue procurement are anticipated to further restrain supply chains.
• Contamination Risks and Shorter lifespan: The higher risk of contamination and the shorter lifespan of primary cells compared to immortalized cell lines are likely to restrain the market. These limitations are expected to increase operational challenges for laboratories, reducing the efficiency of long-term studies.

Key Trends:

• Focus on Stem Cell Research: The rising emphasis on stem cell research is expected to significantly influence the primary cell culture market, given the need for high-quality primary cells in regenerative medicine. This trend is likely to enhance investment in research and development across the biotechnology and pharmaceutical sectors.
• Collaboration between Academia and Industry: Growing partnerships between academic institutions and biopharmaceutical companies are projected to boost the primary cell culture market. These collaborations are anticipated to drive innovation and expedite the commercialization of new cell-based therapies and research tools.
• Demand for Advanced Tissue Engineering: The high demand for advanced tissue engineering solutions is expected to drive the adoption of primary cell cultures in research and clinical applications. This trend is likely to open new avenues for developing organoids and bioengineered tissues, further expanding market potential.

Global Primary Cell Culture Market Regional Analysis

Here is a more detailed regional analysis of the global primary cell culture market:

North America:

• According to Verified Research Market Analyst, North America is anticipated to dominate the primary cell culture market due to the presence of advanced biotechnology and pharmaceutical industries.
• The United States is projected to lead the regional market, driven by increasing investments in research and development, as well as the growing focus on personalized medicine and drug discovery.
• A well-established healthcare infrastructure and strong academic-industry collaborations are expected to further support market growth in this region.
• The rising prevalence of chronic diseases such as cancer is also likely to drive demand for primary cell cultures in North American research institutions. The American Cancer Society estimates that there will be 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2024.

Asia Pacific:

• The Asia Pacific region is estimated to experience the fastest growth in the primary cell culture market, driven by the rising investment in biotechnology and pharmaceutical sectors in countries such as China, Japan, and India.
• According to VMR, Biotechnology Market size was valued at USD 1023.92 Billion in 2023 and is projected to reach USD 2590.03 Billion by 2032, growing at a CAGR of 12.3% from 2026 to 2032.
• The increasing government initiatives to promote life sciences research, along with the expanding clinical research activities, are projected to propel market growth in the region.
• China's growing biotechnology industry, combined with its focus on innovation and healthcare, is anticipated to significantly boost the market for primary cell cultures.
• India is also likely to witness rapid growth, driven by a rising number of pharmaceutical companies and a growing focus on drug development and testing.

Global Primary Cell Culture Market: Segmentation Analysis

The Global Primary Cell Culture Market is Segmented on the basis of Product, Application, Cell Type, And Geography.

Primary Cell Culture Market, By Product

• Primary Cell
• Reagents And Supplements
• Media

Based on Product, the market is bifurcated into Primary Cell, Reagents And Supplements, and Media. The media segment is anticipated to hold the largest share of the primary cell culture market due to its critical role in supporting cell growth, proliferation, and differentiation. Media is projected to experience sustained demand as it is essential for maintaining the viability and functionality of primary cells throughout research and production processes.

Primary Cell Culture Market, By Application

• Vaccine Production
• Stem Cell Therapy
• Cancer Research

Based on Application, the Global Primary Cell Culture Market is divided into Vaccine Production, Stem Cell Therapy, and Cancer Research. The vaccine production segment is projected to hold the largest share of the primary cell culture market. The increasing use of primary cells in the development and production of vaccines is anticipated to drive this growth. Primary cells are widely used due to their ability to mimic natural human cell environments, which is crucial for creating vaccines that are safe and effective.

Primary Cell Culture Market, By Cell Type

• Animal Cells
• Human Cells

Based on Cell Type, the market is segmented into Animal Cells and Human Cells. Human cells are anticipated to hold the largest share of the primary cell culture market, driven by their increasing application in drug discovery, personalized medicine, and cancer research. The demand for human primary cells is projected to rise due to their ability to provide more accurate and clinically relevant models for studying human physiology and disease.

Primary Cell Culture Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the global primary cell culture market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest share of the primary cell culture market, driven by its advanced biotechnology and pharmaceutical industries. The region is projected to maintain its dominance due to the increasing focus on personalized medicine and rising investments in drug discovery and development.

Key Players

The "Global Primary Cell Culture Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Merck KGaA, Lonza, Corning Incorporated, Danaher Corporation, GE Healthcare, PromoCell GmbH, American Type Culture Collection, FUJIFILM Irvine Scientific, MatTek Ltd, Axol Bioscience Ltd, STEMCELL Technologies Inc, Cell Biologics, ZenBio, ScienCell Research Laboratories, and PPA Research Group. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Latest Developments

• In March 2024, Lonza announced a collaboration with a renowned biopharmaceutical company to develop a new cell culture medium tailored exclusively for breakthrough cell therapy.
• In February 2024, Thermo Fisher Scientific introduced a new line of cryopreserved primary human hepatocytes, seeking to give researchers with a more consistent and trustworthy source of these cells for drug discovery applications.
• In February 2024, Corning Incorporated expanded its portfolio of Transwell(R) co-culture devices, which are intended to increase the efficiency and accuracy of cell-based assays used in drug development.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRIMARY CELL CULTURE MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRIMARY CELL CULTURE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PRIMARY CELL CULTURE MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Primary Cell
• 5.3 Reagents And Supplements
• 5.4 Media

6 GLOBAL PRIMARY CELL CULTURE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Vaccine Production
• 6.3 Stem Cell Therapy
• 6.4 Cancer Research
• 6.5 Others

7 GLOBAL PRIMARY CELL CULTURE MARKET, BY CELL TYPE

• 7.1 Overview
• 7.2 Animal Cells
• 7.3 Human Cells

8 GLOBAL PRIMARY CELL CULTURE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL PRIMARY CELL CULTURE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Lonza
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merck KGaA
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Axol Bioscience Ltd
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 GE Healthcare
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 STEMCELL Technologies Inc
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Cell Biologics
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 ZenBio
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 ScienCell Research Laboratories
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 PPA Research Group
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research